Here is why AbCellera Biologics Inc. (ABCL) stock volatility recorded over the last month was 7.10% – Invest Chronicle

Here is why AbCellera Biologics Inc. (ABCL) stock volatility recorded over the last month was 7.10%

At the end of the latest market close, AbCellera Biologics Inc. (ABCL) was valued at $6.64. In that particular session, Stock kicked-off at the price of $6.48 while reaching the peak value of $6.95 and lowest value recorded on the day was $6.10. The stock current value is $6.00.Recently in News on May 10, 2022, AbCellera Reports Q1 2022 Business Results. Total revenue of $317 million, compared to $203 million in Q1 2021. You can read further details here

AbCellera Biologics Inc. had a pretty Dodgy run when it comes to the market performance. The 1-year high price for the company’s stock is recorded $14.79 on 01/03/22, with the lowest value was $5.74 for the same time period, recorded on 05/11/22.

Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '22.
Small-cap Uranium stocks are booming in 2022! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here. .


AbCellera Biologics Inc. (ABCL) full year performance was -76.50%

Price records that include history of low and high prices in the period of 52 weeks can tell a lot about the stock’s existing status and the future performance. Presently, AbCellera Biologics Inc. shares are logging -83.36% during the 52-week period from high price, and -1.64% higher than the lowest price point for the same timeframe. The stock’s price range for the 52-week period managed to maintain the performance between $6.10 and $36.05.

The company’s shares, operating in the sector of Healthcare managed to top a trading volume set approximately around 3273872 for the day, which was evidently higher, when compared to the average daily volumes of the shares.

When it comes to the year-to-date metrics, the AbCellera Biologics Inc. (ABCL) recorded performance in the market was -53.57%, having the revenues showcasing -28.14% on a quarterly basis in comparison with the same period year before. At the time of this writing, the total market value of the company is set at 1.97B, as it employees total of 386 workers.

The Analysts eye on AbCellera Biologics Inc. (ABCL)

During the last month, 6 analysts gave the AbCellera Biologics Inc. a BUY rating, 0 of the polled analysts branded the stock as an OVERWEIGHT, 0 analysts were recommending to HOLD this stock, 0 of them gave the stock UNDERWEIGHT rating, and 0 of the polled analysts provided SELL rating.

According to the data provided on, the moving average of the company in the 100-day period was set at 9.68, with a change in the price was noted -7.63. In a similar fashion, AbCellera Biologics Inc. posted a movement of -55.73% for the period of last 100 days, recording 1,904,645 in trading volumes.

Total Debt to Equity Ratio (D/E) can also provide valuable insight into the company’s financial health and market status. The debt to equity ratio can be calculated by dividing the present total liabilities of a company by shareholders’ equity. Debt to Equity thus makes a valuable metrics that describes the debt, company is using in order to support assets, correlating with the value of shareholders’ equity The total Debt to Equity ratio for ABCL is recording 0.00 at the time of this writing. In addition, long term Debt to Equity ratio is set at 0.00.

Technical rundown of AbCellera Biologics Inc. (ABCL)

Raw Stochastic average of AbCellera Biologics Inc. in the period of last 50 days is set at 6.66%. The result represents downgrade in oppose to Raw Stochastic average for the period of the last 20 days, recording 9.33%. In the last 20 days, the company’s Stochastic %K was 9.10% and its Stochastic %D was recorded 10.21%.

Considering, the past performance of AbCellera Biologics Inc., multiple moving trends are noted. Year-to-date Price performance of the company’s stock appears to be encouraging, given the fact the metric is recording -53.57%. Additionally, trading for the stock in the period of the last six months notably deteriorated by -56.69%, alongside a downfall of -76.50% for the period of the last 12 months. The shares increased approximately by -17.41% in the 7-day charts and went up by -26.55% in the period of the last 30 days. Common stock shares were lifted by -28.14% during last recorded quarter.

Leave a Comment

Your email address will not be published.

On Key

Related Posts